Functional Constipation When OTC Osmotic and Stimulant Laxatives Have Not Achieved Durable Relief

This protocol targets the clinical situation in which a patient with functional constipation has not achieved adequate, sustained improvement on standard over-the-counter laxative therapy. A defined next-line approach exists for this scenario.

First-Line Treatment — Failure Condition

The initial management of functional constipation uses over-the-counter osmotic and stimulant laxatives, including:

Polyethylene glycol (PEG)
Magnesium oxide
Senna
Bisacodyl
Sodium picosulfate

Goals this line must reach:

An increase in complete spontaneous bowel movements and spontaneous bowel movements per week, with response durable over 6 months.

When these goals are not met — or the patient does not tolerate this regimen — escalation to the next step is indicated.

Next-Line Approach

For adults with functional constipation who have failed or cannot tolerate over-the-counter therapies, the structured protocol involves a specific osmotic agent — lactulose — as the primary intervention. The clinical goal is global relief of constipation symptoms and a higher responder rate. The complete regimen, decision criteria, and management algorithm are detailed in the full protocol.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1053/j.gastro.2023.03.214

In adults with CIC who fail or are intolerant to OTC therapies, the panel suggests the use of lactulose over management without lactulose (conditional recommendation, very low certainty of evidence).
It is approved by the FDA in the United States for the treatment of constipation at a dose of 10–20 g (15–30 mL or 1–2 packets) daily and is widely available in other countries.
The dose may be increased to 40 g (60 mL or 2–4 packets) daily if needed.
A second study, however, showed that lactulose may be associated with a large increase in global relief (RR 2.42, CI 1.29–4.54, in absolute terms, 473 more per 1,000, CI 97 more to 1,000 more).

View source ↗